Anticoagulants with antiplatelets ‘questionable’ in some with AF
Large registry study suggests higher risk of stroke and bleeding on dual therapy
To their possible detriment, a sizable minority of patients with non-valvular AF are receiving oral anticoagulants (OAC) in addition to antiplatelet drugs, according to data from an AF registry.
“In the large multinational GARFIELD study, we found that approximately one in eight patients with AF are newly prescribed antiplatelet therapy along with anticoagulation, with or without cardiovascular indications for the antiplatelet therapy,” said lead author Dr Keith Fox of the University of Edinburgh, Scotland.
